A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors Meeting Abstract
| Authors: | Tolcher, A.; Hafez, N.; Yamamoto, N.; Park, J.; Grempler, R.; Lucarelli, A.; Vallaster, M. P.; Wang, B. S.; Hyman, D. |
| Abstract Title: | A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors |
| Meeting Title: | AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
| Journal Title: | Molecular Cancer Therapeutics |
| Volume: | 18 |
| Issue: | 12 Suppl. |
| Meeting Dates: | 2019 Oct 26-30 |
| Meeting Location: | Boston, MA |
| ISSN: | 1535-7163 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-12-01 |
| Language: | English |
| ACCESSION: | WOS:000510047200289 |
| DOI: | 10.1158/1535-7163.Targ-19-c047 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: C047 -- Source: Wos |
